Meeting
2020 ASCO Virtual Scientific Program
Safety, tolerability, and preliminary pharmacokinetic/pharmacodynamic profile of JMT103 in patients with bone metastases from solid tumors: A multicenter, open-label, dose-escalation, phase I clinical study.
Authors
Jin Li
Department of Medical Oncology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China
Jin Li , Huiping Li , Shukui Qin , Ye Guo , Xu Liang , Junli Xue , Wei Peng , Xiaoxiao Ge , Changxing Xie , Xiugao Yang , Tao Li , Jinglin Xu , Li Feng , Zhufeng Wu , Guanxi Xiao , Peng Zhang , Tianyi Zhang , Chenchen Wang , Baoxia Zhang , Zijian Hu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Other Developmental Therapeutics
Clinical Trial Registration Number
NCT03550508
Citation
J Clin Oncol 38: 2020 (suppl; abstr 3638)
DOI
10.1200/JCO.2020.38.15_suppl.3638
Abstract #
3638
Poster Bd #
368
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
A phase I, open-label, multicenter dose escalation study to assess the safety, tolerability, and pharmacokinetics of AZD2811 nanoparticle in patients with advanced solid tumors.
First Author: Melissa Lynne Johnson
Poster
2012 ASCO Annual Meeting
A phase I, single-institution, open-label, dose escalation trial with an expansion cohort evaluating the safety and tolerability of AZD6244 and IMC-A12 in subjects with advanced solid malignancies.
First Author: Shabina Roohi Ahmed
Poster
2023 ASCO Annual Meeting
Sudocetaxel zendusortide (TH1902), a novel sortilin-receptor (SORT1)-targeting peptide-drug-conjugate (PDC) in patients (pts) with advanced solid tumors: Results from part 1 (dose-escalation) of a phase 1, open-label study.
First Author: Funda Meric-Bernstam
Poster
2023 ASCO Annual Meeting
![FRONTIER: FAPi radioligand open-label, phase 1 study to evaluate safety, tolerability and dosimetry of [Lu-177]-PNT6555—A dose <i>e</i>scalation study for treatment of patients with select solid tumors.](https://d201v5jt9ylckg.cloudfront.net/299/15000/225830/225830_A945_poster_pv.jpg)
FRONTIER: FAPi radioligand open-label, phase 1 study to evaluate safety, tolerability and dosimetry of [Lu-177]-PNT6555—A dose escalation study for treatment of patients with select solid tumors.
First Author: Lisa Bodei